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Background: 10-Hydroxycamptothecin (10-HCPT), isolated from a Chinese tree Camptotheca acuminate, inhibits the
activity of topoisomerase I and has a broad spectrum of anticancer activity in vitro and in vivo. It has been shown
that HCPT is more active and less toxic than conventional camptothecins and can induce cancer cell apoptosis.
However, the mechanisms of HCPT-induced apoptosis in colon cancer cells remain unclear. In this study, we
investigated the effects of HCPT on apoptosis of colon cancer and underlying mechanism.
Methods: Cell proliferation was measured by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)
assay, and apoptosis was measured using terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end
labeling (TUNEL) assay. Expression of genes was detected using real-time reverse transcription-polymerase chain
reaction (real time-PCR) and Western blot. Tumor growth in vivo was evaluated using a nude mouse xenograft
model.
Results: HCPT could significantly inhibit cell proliferation and induce apoptosis in colon cancer SW1116 and Colo
205 cells in dose- and time-dependent manners. HCPT treatment activated the activities of caspase 3, 7, 8 and 9,
downregulated the expression of survivin, survivinΔEx3, survivin-3B and XIAP, and upregulated expression of
surviving 2B. Moreover, the combination of HCPT and 5-fluorouracial (5-FU) synergistically induced apoptosis and
downregulated the expression of survivin and XIAP. Knockdown of survivin and XIAP by siRNA sensitized colon
cancer to HCTP-induced apoptosis. Furthermore, HCPT treatment significantly inhibited SW1116 xenograft tumor
growth.
Conclusions: Our results elucidate new mechanisms of HCPT antitumor by the downregulation of survivin and
XIAP expression. The combination of HCPT with 5-FU or IAP inhibitors may be a potential strategy for colon cancer
treatment.
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Colorectal cancer (CRC) is one of the most common can-
cers in the world [1,2]. Even with the development of bio-
logical agents and chemotherapy, colorectal cancer (CRC)
is still a major cause of mortality in cancer patients. There-
fore, developing new therapeutic drugs for advanced colon
cancer remains a challenge. DNA topoisomerases (Topo)
are enzymes that regulate the overwinding or underwinding* Correspondence: wengyuan13b@gmail.com
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reproduction in any medium, provided the orof DNA and are essential to maintaining the helical struc-
ture of DNA [3]. Topo-I cuts a single strand of DNA to
allow the relaxation of torsional stresses before re-
annealing. Studies have shown that Topo-I is highly
expressed in around half of colorectal cancers [4] and that
genomic amplification of Topo-I is correlated with the in-
creased RNA and protein expression of Topo-I in colorec-
tal cancer [5]. Therefore, Topo-I has become a target for
cancer therapy [6,7].
A natural indole alkaloid extracted from a Chinese tree
Camptotheca cuminata, 10-hydroxycamptothecin (HCPT)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of a cleavable drug, Topo-I-DNA complex, results in the le-
thal breakage of double-strand DNA and cell death [3,6-8].
HCPT has a broad spectrum of anti-tumor activity against a
panel of solid tumors in the in vitro and in vivo animal
models and human cancer patients [8-10]. However, de
novo or acquired clinical resistance to camptothecins (CPTs)
is common [11-14]. Little is known about the mechanisms
of HCPT anti-tumor effects and the development of drug
resistance in human colon cancer.
HCPT exhibits strong anti-cancer effects and is less
toxic than CPT [12]. Previous studies indicate that HCPT
and its analogs can stabilize the reversible covalent DNA-
Topo-I complex, resulting in apoptosis of cancer cells
[10,11]. HCPT exhibits high S phase-specific cytotoxicity
and induces G2-M cell cycle arrest [3,15]. Further studies
show that HCPT-induced replication fork collision con-
tributes to S phase cytotoxicity. HCPT exhibits an inhibi-
tory effect on the phosphorylation of histone H1 and H3
in murine hepatoma cells, which results in its specific cell
killing effect [16]. It also exhibits a differentiation inducing
effect in human HepG2 cells [17]. Studies show that
camptothecin inhibits gastric cancer growth and induces
apoptosis by the upregulation of p53, p21Waf1/Cip1 and
p27Kip1 and the downregulation of Bcl-2 and Bcl-XL [18].
These studies have suggested that the anti-cancer function
of HCPT is not consistent with the inhibition of Topo-I
activity, which implies that additional mechanisms are in-
volved in HCPT-induced cell death.
Accumulating data show that HCPT can induce apop-
tosis in multiple cancers [19] and can inhibit metastatic
colorectal cancer [20,21]. The studies have shown that the
combination of 5-fluorouracil (5-FU) with Topo-I inhibi-
tor remains as one of the main treatments for advanced
cancer [21,22]. However, the mechanisms of the combin-
ation of HCPT and 5-FU remain largely unknown. In this
study, we investigated the effects of HCPT alone or in
combination with 5-FU on colon cancer growth and the
underlying mechanisms involved.
Methods
Cell culture and reagents
The human colon cancer cell lines SW1116 and Colo 205
were obtained from ATCC (Rockville, MD, USA) and
maintained in a Roswell Park Memorial Institute (RPMI)-
1640 medium containing 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 μg/mL streptomycin (Gibco
BRL, Life Technologies, NY, USA). HCPT and 5-FU pur-
chased from Sigma (St. Louis, MO, USA) were dissolved
in dimethyl sulfoxide (DMSO) and stored at 4°C.
Cell proliferation assay
Cell proliferation was determined using 3(4,5 dimethylthiazol)-
2,5 diphenyltetra-zolium (MTT) assay; 100 μL SW1116and Colo 205 cells in exponential growth at 1 × 104/mL
were seeded into flat-bottomed 96-well plates (NUNC) 24
hours prior to the drug treatment. Cells were treated with
0.1 μg/mL to 10 μg/mL HCPT in triplicate for 48 hours.
After washing, the medium was replaced by 100 μL RPMI
1640 (GIBCO) medium containing 1 mg/mL MTT
(Sigma). After 4 hours, the plates were centrifuged at 800 ×
g for 5 minutes, the MTT medium was removed, and the
purple formazan crystals were dissolved in 200 μL of warm
DMSO per well. After 10 minutes, the plates were read on
the microplate reader (American Bio-Tek) at 570 nm. The
cells without drugs were used as the control. The survival
of the cells was expressed as the percentage of untreated
control wells. Assays were performed on three independent
experiments.
Transfections of survivin shRNA and X-linked inhibitor of
apoptosis protein shRNA
Colon cancer SW1116 cells (2 × 105 per well) were
seeded on a six-well tissue culture plate for 24 hours
prior to transfection. The SW1116 cells were transfected
with 50 pmols survivin siRNA (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) or X-linked inhibitor of
apoptosis protein (XIAP) siRNA (Santa Cruz Biotechnol-
ogy) using siRNA Transfection Reagent (Santa Cruz Bio-
technology, sc-29528) for 6 hours according to the
manufacturer’s instruction. Then cells were incubated
with HCPT at 1 mL of normal growth medium for an
additional 24 or 48 hours. Cells were harvested for apop-
tosis analysis using TUNEL or for western blot analysis.
Apoptosis assays
Apoptosis was assessed by 2´-deoxyuridine, 5´-triphos-
phate (dUTP) labeling of DNA nicks with terminal
deoxynucleotidyl transferase (TUNEL). Colon cancer
cells (3 × 105/well) were inoculated into 6-well plates
with previously placed glass slides. After 24 hours, cells
were treated with HCPT in the presence or absence of
capase-3 inhibitor z-DEVD-fmk. At 24 hours and 48
hours after the treatment with HCPT, glass slides with
cancer cell growth were fixed with 4% polyformaldehyde.
The TUNEL assay was performed according to the in-
structions in the Apoptosis Detection Kit (Boehringer-
Mannheim, Germany). Briefly, after washing twice with
pH 7.4 PBS, 50 μL TUNEL reaction solutions were
added to the well, and then incubated at 37°C for 2
hours. After the substrate had reacted, stained cells were
examined under the light microscopy. Apoptotic cells
were scored and expressed as the number of positively
stained cells per 400 cells (n = 5).
Real-time PCR
After drug treatment, cells were harvested for RNA ex-
traction. RNA was prepared using the RNeasy mini kit
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of DNA contamination (QIAGEN, Valencia, CA, USA).
cDNA was prepared from 500 ng of RNA (TaqMan Re-
verse Transcription Reagents, ABI/Roche, Branchburg, NJ,
USA), based on the manufacturer’s instructions. The tem-
plate cDNA (12.5 ng/sample) for control and HCPT was
mixed with Syber green master mix (Life Technologies,
Grand Island, NY, USA). Mixtures were aliquoted into 96-
well optical reaction plates (ABI) along with the forward
and reverse primers for each target gene. Samples were
run in triplicates. Primers were designed using ABI primer
express software. Survivin forward primers: 5′-AGAAC
TGGCCCTTCTTGG AGG-3′; reverse: 5′-CTTTTTATG
TTCCTCTATGGGGTC-3′; XIAP forward primers: 5-AA
TAGTGCCACGCAGTCTACA-3′, reverse: 5′-CAGATG
GCCTGTCTAAGGCAA-3′; GAPDH forward primers:
5′-TG TGGGCATCAATGGATTTGG-3′, reverse: 5′-AC
ACCA TGTATTCCGGGTCAAT-3′. Survivin-ΔEX3 for-
ward primers: 5 ′-ATGACGACCCCATG CAAAG-3′ and
reverse: 5-GGTGGCACCAGGGAATAAAC-3′; survivin-
2B forward primers: 5′-GCGGATCACGAG AGAGGA-3′
‘and reverse: 5′-TCTCCGCAGTTTCCTCA AAT-3′;
Survivin-3B forward primers: 5′-CCTTTCTGTCAAG
AAGCAGTTTG−3′, reverse: 5′-TGCTAACAGAGCTC
TCTCAATTT-3′; Survivin-2α forward primers:5′-CT
ACATTC AAGAACTGGCCCTT-3′; reverse, 5′-CAGCT
CCTTGAAGCAGAAGAA-3′. Data were analyzed using
the comparative cycle threshold (CT) method, by which
the fold change of target gene samples (HCPT treatment)
that was normalized to the housekeeping gene (beta-actin)
relative to the calibrator (control) is calculated using the
2-ΔΔCT equation, where ΔΔCT = ΔCT (sample) - ΔCT
(calibrator), and ΔCT is the CT value of the target gene
subtracted from the CT value of the housekeeping gene.
All the values were determined in the exponential phase
of the reactions.Western blot analysis
Colon cancer cells were lysed with the lysis buffer (50
mM Tris–HCl (pH 7.5), 250 mM NaCl, 0.1% NP40, 5
mM EGTA containing 50 mM sodium fluoride, 60 mM
β-glycerol-phosphate, 0.5 mM sodium vanadate, 0.1 mM
phenylmethylsulfonyl fluoride, 10 μg/mL aprotinin, and
10 μg/mL leupeptin). Protein samples were electro-
phoresed in a 10% denaturing SDS gel and transferred to
Immobilon-P membrane (Millipore, Bedford, MA, USA).
The blots were first incubated with specific primary
antibodies XIAP, survivin, c-IAP-1, c-IAP-2, cleaved
Caspase-3, 8, 9, cytochrome c antibodies (Cell Signaling
Technology, Danvers, MA, USA), then reacted with a
peroxidase-conjugated secondary antibody (Santa Cruz
Biotechnology), and finally visualized by enhanced chemi-
luminescence (Amersham, Piscataway, NJ, USA).Colon tumor xenograft models and treatment
Four-week-old female BALB/nude mice from Animal
Experimental Center of Shanghai Institute of Biological
Sciences (Shanghai, China) were maintained in a steril-
ized animal room in our animal facility. Colon cancer
cells SW1116 (1 × 106) were injected subcutaneously (s.
c.) into the flank of BALB/nude mice. The mice either
received a daily intrapertioneal (i.p.) injection of HCPT
(7.5 mg/kg body weight) or a 5-FU (10 mg/kg body
weight) separately or in combination after tumors
reached a size of 50 mm3 to 60 mm3. Tumor sizes were
measured by a caliper weekly. Tumor tissues were
harvested at the end of the experiments. Animal proto-
cols were approved by the Animal Care and Facilities
Committee (ACFC) of No.4 People’s Hospital of Wuxi
City, China.
Statistical analysis
Unless indicated otherwise, all experiments were
conducted at least thrice with at least five mice per
group. Results, expressed as means ± SD, were analyzed
for differences between the two groups using a two-
tailed t-test with assumption of equal variances, with a
P-value of <0.05 deemed significant. One-way analysis of
variance (ANOVA) was used to compare the results of
three or more groups.
Results
HCPT inhibits colon cancer proliferation
The effect of HCPT on the viability of colon cancer cells
was determined by the MTT assay. HCPT exhibited
strong cytotoxic effects on colon cancer cells. HCPT
inhibited cell proliferation of colon cancer in time- and
dose-dependent manners (Figure 1A and 1B). HCPT
had similar inhibition effects on SW1116 and Colo 205
cells. The IC50 of HCPT on SW1116 and Colo 205 cells
were 3.3 μg/mL and 3.8 μg/mL respectively. These re-
sults suggest that HCPT could inhibit cell proliferation.
HCPT induces apoptosis in colon cancer cells
Six hours after exposure to HCPT, colon cancer cells
SW1116 and Colo 205, began to show morphologic fea-
tures of apoptosis. The apoptotic cells increased follow-
ing a prolongation of exposure time to drugs. The
features of apoptosis that were observed in SW1116
cells, included cell shrinkage, cytoplasmic blebs, conden-
sation of chromatin, nuclear condensation, fragmenta-
tion of the nucleus and the formation of apoptotic
bodies (data not shown). TUNEL staining showed that
HCPT induced apoptosis in SW1116 and Colo 205 cells
in a time- and dose-dependent manner (Figure 2A-2C).
After 48 hours of exposure to 5 μg/mL HCPT, the apop-
totic rates of SW1116 and Colo 205 were 36.4% and
















































Figure 1 HCPT inhibits cell proliferation. Colon cancer cells were
treated with 10-hydroxycamptothecin (HPCT) at the indicated dose
(A) or at the indicated time (B). Cell inhibition was measured by MTT







































































Figure 2 HCPT induces apoptosis in colon cancer cells. SW1116
(A) and Colo 205 (B) were treated with 10-hydroxycamptothecin
(HCPT) (2.5 μg/mL) at the indicated time. Apoptosis was determined
by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick
end labeling (TUNEL) staining. The data represent the means ± SD
from three independent experiments; *P <0.01, compared to the PBS
group. (C) SW1116 and Colo 205 were treated with HCPT (2.5 μg/
mL) at the indicated dose for 48 hours. Apoptosis was determined
by TUNEL staining. The data represent the means ± SD from three
independent experiments; *P <0.01, compared to PBS treatment.
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of SW1116 were 23.4%, 36.7% and 49.8% respectively.
HCPT activates intrinsic and extrinsic apoptotic pathways
To characterize the signaling pathways by which HCPT
induces apoptosis in colon cancer cells, we further
determined the activities of caspase-3 in the HCPT-
treated SW1116 cells. The data revealed that HCPT sig-
nificantly increased the activity of caspase 3 in SW1116
cells (Figure 3A). To further investigate if HCPT acti-
vated intrinsic and extrinsic pathways during apoptosis,
we determined the expression of the cleavage of caspase-3,
caspase-7, caspase-9 (a caspase in the intrinsic pathway),
caspase-8 (a caspase in the extrinsic pathway) and poly
(ADP-ribose) polymerase (PARP). Western blot showed
that HCTP treatment increased the expression of cleaved
caspases and the release of cytochrome c (Figure 3B). To
determine whether HCPT induce apoptosis through a
caspase-dependent manner, we pre-treated SW1116 cells
with caspase 3 inhibitor z-DEVD-fmk for 2 hours and
then treated them with HCPT for another 48 hours. Wefound that z-DEVD-fmk treatment significantly inhibited
HCPT-induced apoptosis of colon cancer cells (Figure 3C).
The data indicate that HCPT induces apoptosis of colon
cancer cells through both extrinsic and intrinsic apoptotic
pathways.
HCPT inhibits expression of XIAP and survivin in colon
cancer cells
Inhibitors of apoptosis (IAPs) are endogenous inhibitors
of caspases and are related to chemo-resistance in some
cancer cells, including colon cancer [2-6]. Furthermore,
the targeted downregulation of XIAP or survivin genes has
been shown to directly sensitize cancer cells to apoptosis



































































Figure 3 HCPT activates the intrinsic and extrinsic apoptotic
pathways. (A) 10-hydroxycamptothecin (HCPT) increased the
activity of caspase 3. SW1116 cells were treated with 2.5 μg/mL
HCPT for 48 hours. Cells were harvested for caspase 3 activity assay.
The data are the means ± SD from two independent experiments.
*P <0.01, compared to PBS group. (B) HCPT activated the intrinsic
and extrinsic apoptotic pathways. SW1116 cells were treated with
2.5 μg/mL HCPT for 48 hours. Protein expressions were determined
by western blot. (C) HCPT induces apoptosis in a caspase-dependent
manner. SW1116 cells were pre-treated with z-DEVD-fmk for 2 hours
and then treated with HCPT (10 μg/mL) for another 48 hours.
Apoptosis was determined by terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick end labeling (TUNEL) staining. The data
represent the means ± SD from three independent experiments.
*P <0.01, compared to DMSO groups.
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caspase activity and the induction of apoptosis by HCPT
are due to the inhibition of IAPs. We determined theexpressions of XIAP and survivin in HCPT-treated
SW1116 cells. Western blot showed that HCPT sig-
nificantly inhibited the expression of XIAP and survivin,
but did not affect expression of c-IAP-1 and c-IAP-2
(Figure 4A), suggesting that survivin and XIAP are the tar-
gets of HCPT. In addition, we also determine the effects of
HCPT on the expression of survivin splices. Real-time
PCR showed that HCPT downreguated the expression of
survivin 3B and survivin-ΔEx3, and upregulated the ex-
pression of survivin 2B (Figure 4B). These results suggest
that HCPT has different effects on survivin splices.
To further characterize the roles of XIAP and survivin
in HCPT-induced apoptosis, we silenced XIAP and
survivin expression in SW1116 cells. The expressions of
both proteins were downregulated by 72% 48 hours after
siRNA transfections (Figure 4C and 4D). Under the same
transfections, we treated SW1116 cells with HCPTand de-
termined apoptosis. The knockdown of XIAP or survivin
expression significantly increased HCPT-induced apop-
tosis in SW1116 cells (Figure 4E and 4F). These results
suggest that the downregulation of XIAP and survivin are
the major mechanisms by which HCPT induces apoptosis.
The combination of HCPT and 5-FU synergistically
induces apoptosis in colon cancer cells
Clinical studies have shown that the combination of HCPT
and 5-FU increases the response of patients with advanced
colon cancer [22]. However, the underlying mechanisms
are not fully understood. We determined the effects of the
combination of HCPT and 5-FU on apoptosis and the ex-
pression of XIAP and survivin. The SW1116 cells and Colo
205 cells were treated with HCPT or 5-FU alone or in
combination, and apoptosis was determined. The results
showed that the combination of HCPT and 5-FU signifi-
cantly increased apoptosis of SW1116 and Colo 205 cells
more than HCPT or 5-FU treatment (Figure 5A). The ex-
pression of XIAP and survivin also markedly decreased in
the cells treated with the combination of HCPT and 5-FU
than in those treated with HCPT or 5-FU treatment alone
(Figure 5B and 5C). The data indicate that the combination
of HCPT and 5-FU synergistically induces apoptosis in
colon cancer cells through the downregulation of XIAP
and survivin.
The combination of HCPT and 5-FU synergistically inhibits
xenograft growth in colon cancer cells
Finally, we further investigated the effects of HCPT alone
or in combination with 5-FU on tumor growth in vivo.
SW1116 cells were injected into BABL/c nude mice. When
tumor size reached 50 mm3 to 60 mm3, the mice were
injected i.p. with HCPT (5 mg/kg body weight), 5-FU (10
mg/kg), the combination of HCPT and 5-FU, or PBS (con-
trol) for five days. The results showed that HCPT and 5-













































































































































































Figure 4 HCPT downregulates the expression of survivin and XIAP and in colon cancer cells. (A) SW1116 cells were treated with
10-hydroxycamptothecin (HCPT) (2.5 μg/mL) for 48 hours. Expression of survivin, X-linked inhibitor of apoptosis protein (XIAP), c-inhibitor of
apoptosis (IAP)-1 and c-IAP-2 were determined by western bot. (B) SW1116 cells were treated with HCPT for 48 hours. Expression of survivin
splices was determined by real-time PCR; *P <0.05, #P >0.05, compared to the control group. (C-D) Knockdown of survivin and XIAP by siRNA.
SW1116 cells were transfected with Survivin siRNA (C), and XIAP siRNA (D). Twenty-four hours after transfection, cells were treated with HCPT for
another 48 hours. The mRNA expression of survivin (C) and XIAP (D) was measured by real-time PCR. (E-F) Knockdown of survivin and XIAP
enhanced HCPT-induced apoptosis. SW1116 cells were transfected with Survivin siRNA (E), and XIAP siRNA (F). Then, cells were treated with HCPT
for another 48 hours. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL)
staining; *P <0.01, compared to the control siRNA groups; *P <0.01, compared to the PBS group.
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ment synergistically inhibited tumor growth compared to
HCPT and 5-FU treatment alone (Figure 6). The combin-
ation of HCPT and 5-FU synergistically inhibits colon can-
cer growth in vivo.
Discussion
HCPT is an agent with an unique spectrum of anti-
tumor activity mediated by a selective inhibition ofeukaryotic DNA Topo-I [7,11]. This inhibition is gener-
ally thought to be mediated by the stabilization of the
CPT-Topo-I-DNA cleavable complex [11]. In this study,
we found that HCPT could inhibit cell proliferation and
also induce apoptosis in colon cancer cells. HCPT in-
duced apoptosis through the intrinsic and extrinsic
apoptotic pathways and the downregulation of survivin
and XIAP expression. HCPT and 5-FU synergistically in-





























































































Figure 5 HCPT enhances colon cancer cells to 5-FU-induced
apoptosis. (A). The combination of 10-hydroxycamptothecin (HCPT)
and 5-fluorouracil (5-FU) synergistically induces apoptosis. SW1116
cells and Colo 205 cells were treated with HCPT (2.5 μg/mL) or 5-FU
(5 μg/mL) alone or in their combination for 48 hours. Apoptosis was
determined by terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labeling (TUNEL) staining. (B-C) The
combination of HCPT and 5-FU synergistically downregulates
expression of X-linked inhibitor of apoptosis protein (XIAP) and
survivin. SW1116 cells were treated with HCPT or 5-FU alone or in
their combination for 48 hours. The mRNA expression of survivin
(B) and XIAP (C) were determined by real-time PCR. The data are the
mean ± SD of three independent experiments. *P <0.05, compared































Figure 6 The combination of HCPT and 5-FU synergistically
inhibits tumor growth in vivo. SW1116 cells were subcutaneously
injected into the flank of athymic nude mice. The tumor at 50 mm3
to 60 mm3 volume was treated with 10-hydroxycamptothecin
(HPCT) by intraperitoneal injection (5 mg/kg), or 5-FU (10 mg/kg) or
a combination of both for 5 days. Tumor growth was measured
every week after the treatment for a duration of 6 weeks. Data are
the means ± SD of tumor size per mouse
(n = 6). *P <0.01, compared to the 5-FU or HCPT treatment alone;
# P <0.05, compared to PBS treatment.
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Our results demonstrate that the important apoptotic
mechanisms are related to the anticancer effects of
HCPT independent from the inhibition of Topo-I.
Two main pathways of apoptosis have been character-
ized to date: one is triggered by death receptors (extrinsic
pathway) [23,24], and the other is the mitochondrial path-
way (intrinsic pathway), which is the main pathway used
for stress-induced apoptosis [25,26]. In the first pathway,
the utilization of adaptors in engaging receptors leads to
the activation of apical caspases, such as caspase-8 [23,24];
in the second pathway, mitochondria have a central rolein initiating apoptosis [27]. Studies have shown that
camptothecin and its analogs can induce apoptosis in hu-
man leukemic cells, colon, prostate, and breast cancer cells
as well as glioma cells [11]. Irinotecan, a Topo-I inhibitor,
induces apoptosis of liver cancer cells through the
downregulation of mutant p53 and the upregulation of
Bax [28]. Irinotecan also may increase p53 transcriptional
activity and induce p53 expression in wild-type p53-
expressing HCT-116 colon cancer cells [29]. A previous
study showed that low-dose HCPT induced apoptosis
through the activation of caspase 3 [15]. Our results
showed that HCPT treatment increased the activities of
caspase 3. Western blot further showed that HCPT could
induce the cleavage of caspase 3, 7, 8, 9. Our results dem-
onstrate that HCPT induces apoptosis of colon cancer
cells through both intrinsic (mitochondrial) and extrinsic
(non-mitochondrial) pathways.
IAPs are endogenous inhibitors of caspases and are asso-
ciated with chemo-resistance in some cancer cells, includ-
ing colon cancer [30]. Survivin and XIAP directly inhibit
the activities of caspase 3. Furthermore, the targeted inhib-
ition of XIAP or survivin genes has been shown to directly
sensitize cancer cells to apoptosis induced by various con-
ventional chemotherapeutic drugs [31,32]. In this study, we
found that HCPT could downregulate expressions of XIAP
and survivin, resulting in the activation of caspase 3 en-
zyme activity and the execution of apoptosis. Moreover,
the downregulation of XIAP or survivin enhanced the
apoptosis induced by HCPT. The results document that
HCPT-induced degradation of XIAP and survivin is the
key event that contributes to HCPT-induced apoptosis. In
addition, we also found that HCPT has different effects on
Fei et al. World Journal of Surgical Oncology 2013, 11:120 Page 8 of 9
http://www.wjso.com/content/11/1/120the expression of surviving splices. It has reported that the
expression of survivn-ΔEx3 and survivin-3B were associ-
ated with lymphoid metastasis and Dukes grade [33] and
that survivin 2B has a function against survivin anti-
apoptosis [34]. Our results showed that HCPT down-
regulated expression of survivin-ΔEx3 and survivin-3B and
upregulated expression of survivin-2B. Our results are
similar to the previous report that doxorubicin upregulated
expression of survivin-2B and downregulated expression of
survivin-ΔEx3 [34], suggesting that survivin is a major tar-
get for HCPT-anti-tumor effects.
Topo-I inhibitor has been used to treat advanced
colon cancer when combined with 5-FU [35]. However,
the effect of the combination of HCPT and 5-FU on
colon cancer growth remains unclear. Our results
showed that the combination of HCPT and 5-FU syner-
gistically induced apoptosis, downregulated the expres-
sion of XIAP and survivin and inhibited colon cancer
growth. Our study elucidates a new mechanism by
which the combination of HCPT and 5-FU treats colon
cancer.
In summary, our current study demonstrates that
HCPT induced cell apoptosis and inhibited cell growth
in human colonic cancer cells. The HCPT-induced cell
apoptosis and the inhibition of growth may involve the
activation of intrinsic and extrinsic apoptotic pathways
and the downregulation of expression of XIAP and
survivin. The combination of HCPT and 5-FU synergistic-
ally induces apoptosis, downregulates XIAP and survivin
expression and inhibits xenograft tumor growth. Our find-
ings in the present study offer a significant groundwork
for future essential clinical application.
Conclusions
Our results elucidate new mechanisms of HCPT anti-
tumor by the downregulation of survivin and XIAP ex-
pression. The combination of HCPT with 5-FU or IAP
inhibitors may be a potential strategy for colon cancer
treatment.
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